EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gene therapy for Lafora disease in the Epm2a mouse model

Luis Zafra-Puerta, Nerea Iglesias-Cabeza, Daniel F Burgos, Miriam Sciaccaluga, Juan González-Fernández, Laura Bellingacci, Jacopo Canonichesi, Gema Sánchez-Martín, Cinzia Costa, Marina P Sánchez, José M Serratosa

Molecular Therapy · 2024-07 · 32 (7) · 2130-2149

DOI: 10.1016/j.ymthe.2024.05.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024-07. Verfasst von Luis Zafra-Puerta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neurology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Sp…. Hauptthemen laut MEDLINE: Lafora Disease, Disease Models, Animal, Genetic Therapy, Protein Tyrosine Phosphatases, Non-Receptor. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke, Tatiana Pérez de Guzmán el Bueno Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lafora disease is a rare and fatal form of progressive myoclonic epilepsy typically occurring early in adolescence. The disease results from mutations in the EPM2A gene, encoding laforin, or the EPM2B gene, encoding malin. Laforin and malin work together in a complex to control glycogen synthesis and prevent the toxicity produced by misfolded proteins via the ubiquitin-proteasome system. Disruptions in either protein cause alterations in this complex, leading to the formation of Lafora bodies containing abnormal, insoluble, and hyperphosphorylated forms of glycogen. We used the Epm2a-/- knockout mouse model of Lafora disease to apply gene therapy by administering intracerebroventricular injections of a recombinant adeno-associated virus carrying the human EPM2A gene. We evaluated the effects of this treatment through neuropathological studies, behavioral tests, video-electroencephalography, electrophysiological recordings, and proteomic/phosphoproteomic analysis. Gene therapy ameliorated neurological and histopathological alterations, reduced epileptic activity and neuronal hyperexcitability, and decreased the formation of Lafora bodies. Moreover, differential quantitative proteomics and phosphoproteomics revealed beneficial changes in various molecular pathways altered in Lafora disease. Our results represent proof of principle for gene therapy with the coding region of the human EPM2A gene as a treatment for EPM2A-related Lafora disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lafora DiseaseDisease Models, AnimalGenetic TherapyProtein Tyrosine Phosphatases, Non-ReceptorMice, KnockoutDependovirusAnimalsMiceHumansGenetic VectorsCarrier ProteinsElectroencephalographyProteomics

Stichwörter der Autor:innen

Epm2a(−/−) knockout mousegene therapylaforinpolyglucosansprogressive myoclonic epilepsyrAAV

Substanzen

Protein Tyrosine Phosphatases, Non-ReceptorEpm2a protein, mouseCarrier ProteinsEPM2A protein, human

Autor:innen und Institutionen

  • Laboratory of Neurology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (C…
  • Section of Neurology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy; Fondazione Malattie Rare Mauro Baschirotto BIRD Onlus, Longare (VI), Italy.
  • Section of Physiology and Biochemistry, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.
  • Section of Neurology, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy.

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • Tatiana Pérez de Guzmán el Bueno Foundation
  • CIBER
  • Instituto de Investigación Sanitaria Fundación Jiménez Díaz
  • National Institutes of Health
  • Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España

Zitieren

APA

Zafra-Puerta, L., Iglesias-Cabeza, N., Burgos, D. F., Sciaccaluga, M., González-Fernández, J., Bellingacci, L., Canonichesi, J., Sánchez-Martín, G., Costa, C., Sánchez, M. P., & Serratosa, J. M. (2024). Gene therapy for Lafora disease in the Epm2a mouse model. Molecular Therapy, 32(7), 2130-2149. https://doi.org/10.1016/j.ymthe.2024.05.032

Vancouver

Zafra-Puerta L, Iglesias-Cabeza N, Burgos DF, Sciaccaluga M, González-Fernández J, Bellingacci L, et al. Gene therapy for Lafora disease in the Epm2a mouse model. Molecular Therapy. 2024;32(7):2130-2149. doi:10.1016/j.ymthe.2024.05.032

BibTeX
@article{ZafraPuerta2024,
  author = {Zafra-Puerta, Luis and Iglesias-Cabeza, Nerea and Burgos, Daniel F and Sciaccaluga, Miriam and González-Fernández, Juan and Bellingacci, Laura and Canonichesi, Jacopo and Sánchez-Martín, Gema and Costa, Cinzia and Sánchez, Marina P and Serratosa, José M},
  title = {Gene therapy for Lafora disease in the Epm2a mouse model},
  journal = {Molecular Therapy},
  year = {2024},
  volume = {32},
  number = {7},
  pages = {2130--2149},
  doi = {10.1016/j.ymthe.2024.05.032}
}
Kostenlos starten →